0.00
Schlusskurs vom Vortag:
$0.0949
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$6.52M
Einnahmen:
$202.00K
Nettoeinkommen (Verlust:
$-28.96M
KGV:
0.00
EPS:
-0.6
Netto-Cashflow:
$-21.85M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Vergleichen Sie AIM mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AIM
AIM ImmunoTech Inc
|
0.00 | 6.52M | 202.00K | -28.96M | -21.85M | -0.60 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
496.44 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.87 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
620.49 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.83 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech files to sell units, no amount given - MSN
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - The Globe and Mail
AIM ImmunoTech Inc. Names Ellen Lintal as New Chief Financial Officer - marketscreener.com
AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN
AIM ImmunoTech appoints Chemerow as an Independent Director - MSN
Aim ImmunoTech CEO Thomas K Equels buys $2,583 in common stock - Investing.com Canada
AIM ImmunoTech begins trading under new ticker AIMI - Investing.com Australia
AIM ImmunoTech begins trading under new ticker AIMI By Investing.com - Investing.com India
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - The Manila Times
AIM ImmunoTech Changes Markets: Key Details of AIMI Ticker Switch and Special Meeting - Stock Titan
Aim Immunotech’s COO Peter Rodino III acquires shares for $43 - Investing.com Australia
Aim Immunotech’s COO Peter Rodino III acquires shares for $43 By Investing.com - Investing.com India
AIM ImmunoTech faces NYSE American delisting over low stock price By Investing.com - Investing.com South Africa
AIM ImmunoTech (AIM) Faces Delisting from NYSE American - GuruFocus
AIM ImmunoTech faces NYSE American delisting over low stock price - Investing.com
AIM ImmunoTech announces NYSE American notice of delisting and appeal - TipRanks
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - GlobeNewswire
NYSE American Suspends AIM ImmunoTech Trading: Company Fighting Delisting Notice - Stock Titan
NYSE American To Commence Delisting Proceedings Against Aim Immunotech Inc - marketscreener.com
NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM) - Business Wire
Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March - Benzinga
AIM ImmunoTech Inc. (AMEX:AIM) Q4 2024 Earnings Call Transcript - Insider Monkey
AIM ImmunoTech’s Earnings Call: Progress Amid Challenges - TipRanks
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strat - GuruFocus
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic - ACCESS Newswire
AIM Immunotech Inc Files For Mixed Shelf Offering Of Up To $100 MillionSEC Filing - MarketScreener
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Earnings Scheduled For March 28, 2025AIM ImmunoTech (AMEX:AIM), China Automotive Systems (NASDAQ:CAAS) - Benzinga
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings Preview For AIM ImmunoTech - Benzinga
AIM ImmunoTech Inc. (AIM) reports earnings - Quartz
AIM Immunotech Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Corporate Update - Marketscreener.com
AIM ImmunoTech Slashes Expenses While Progressing Cancer Trials With AstraZeneca - Stock Titan
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
AIM ImmunoTech Inc. Shares Key Updates on Clinical Trials and Future Plans at Virtual Investor Conference - Nasdaq
AIM ImmunoTech's 5 Game-Changing Programs: Pancreatic Cancer Trial Leads 2025 Strategy - StockTitan
Aim Immunotech CEO Thomas Equels buys $6,730 in stock By Investing.com - Investing.com Canada
Aim Immunotech CEO Thomas Equels buys $6,730 in stock - Investing.com India
What is AIM ImmunoTech Inc (AIM) Stock Return on Shareholders’ Capital? - SETE News
Aim Immunotech CEO Thomas K Equels buys $5,060 in common stock - Investing.com India
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):